Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Finished Goods (2017 - 2019)

Avalo Therapeutics (AVTX) has disclosed Finished Goods for 3 consecutive years, with $46705.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Finished Goods fell 90.62% year-over-year to $46705.0, compared with a TTM value of $46705.0 through Dec 2019, down 90.62%, and an annual FY2019 reading of $46705.0, down 90.62% over the prior year.
  • Finished Goods was $46705.0 for Q4 2019 at Avalo Therapeutics, down from $497949.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $560499.0 in Q4 2017 and bottomed at $46705.0 in Q4 2019.
  • Average Finished Goods over 3 years is $368384.3, with a median of $497949.0 recorded in 2018.
  • The sharpest move saw Finished Goods dropped 11.16% in 2018, then plummeted 90.62% in 2019.
  • Year by year, Finished Goods stood at $560499.0 in 2017, then dropped by 11.16% to $497949.0 in 2018, then tumbled by 90.62% to $46705.0 in 2019.
  • Business Quant data shows Finished Goods for AVTX at $46705.0 in Q4 2019, $497949.0 in Q4 2018, and $560499.0 in Q4 2017.